Polymorphisms in RETN gene and susceptibility to colon cancer in Saudi patients

被引:18
作者
Alharithy, Rowyda N. [1 ]
机构
[1] King Abdulaziz Univ, Dept Biochem, Jeddah 21499, Saudi Arabia
关键词
HUMAN RESISTIN GENE; SERUM RESISTIN; INSULIN-RESISTANCE; COLORECTAL-CANCER; ADIPOSE-TISSUE; PLASMA RESISTIN; G/G GENOTYPE; OBESITY; RISK; PROMOTER;
D O I
10.5144/0256-4947.2014.334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVES: Resistin is an adipocytokine, which has been studied for its role in insulin resistance and recently in inflammation. Several single-nucleotide polymorphisms (SNPs) have been identified in the human resistin gene (RETN). This study aims to investigate the association of RETN rs1862513 (C-420G) and rs3745367 (G+299A) SNPs with the colon cancer risk in Saudi patients. DESIGN AND SETTINGS: This is a case-control study conducted among Saudi adult colon cancer patients recruited from King Abdulaziz Hospital and Oncology Center in Jeddah, Saudi Arabia. SUBJECTS AND METHODS: In this study, 120 Saudi volunteers (60 colon cancer patients and 60 disease-free controls) were studied. The SNPs were determined by polymerase chain reaction (PCR) and genotyping using PCR-restriction fragment length polymorphism analysis. RESULTS: In comparing the result obtained for the patient group with that of the controls, colon cancer group displayed different genotype distribution of the RETN C-420G and G+299A SNPs. The study indicated that the SNP-420 heterozygous (CG) genotype (odds ratio [OR]=2.48, 95% CI 1.07-5.74, P=.03) and the SNP +299 heterozygous (GA) genotype (OR=6.5, 95% CI 1.77-24.18, P=.002) significantly increased the risk of colon cancer. A further analysis of the genotype combination of SNPs RETN C-420G and G+299A showed a larger increase in the colon cancer risk. CONCLUSION: These preliminary results suggested a potential role for RETN C-420G and G+299A polymorphisms in the genetic predisposition to colon cancer disease.
引用
收藏
页码:334 / 339
页数:6
相关论文
共 48 条
[1]  
Al-Harithy RN, 2010, SAUDI MED J, V31, P495
[2]   Correlation between serum resistin level and adiposity in obese individuals [J].
Azuma, K ;
Katsukawa, F ;
Oguchi, S ;
Murata, M ;
Yamazaki, H ;
Shimada, A ;
Saruta, T .
OBESITY RESEARCH, 2003, 11 (08) :997-1001
[3]  
Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
[4]   Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Quebec Family Study [J].
Bouchard, L ;
Weisnagel, SJ ;
Engert, JC ;
Hudson, TJ ;
Bouchard, C ;
Vohl, MC ;
Pérusse, L .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (11) :1003-1009
[5]   Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[6]   Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans [J].
Cho, YM ;
Youn, BS ;
Chung, SS ;
Kim, KW ;
Lee, HK ;
Yu, KY ;
Park, HJ ;
Shin, HD ;
Park, KS .
DIABETOLOGIA, 2004, 47 (03) :559-565
[7]  
de Courten BV, 2004, DIABETES, V53, P1279, DOI 10.2337/diabetes.53.5.1279
[8]   Serum resistin (FIZZ3) protein is increased in obese humans [J].
Degawa-Yamauchi, M ;
Bovenkerk, JE ;
Juliar, BE ;
Watson, W ;
Kerr, K ;
Jones, R ;
Zhu, QH ;
Considine, RV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5452-5455
[9]   Cancer Risks for MLH1 and MSH2 Mutation Carriers [J].
Dowty, James G. ;
Win, Aung K. ;
Buchanan, Daniel D. ;
Lindor, Noralane M. ;
Macrae, Finlay A. ;
Clendenning, Mark ;
Antill, Yoland C. ;
Thibodeau, Stephen N. ;
Casey, Graham ;
Gallinger, Steve ;
Le Marchand, Loic ;
Newcomb, Polly A. ;
Haile, Robert W. ;
Young, Graeme P. ;
James, Paul A. ;
Giles, Graham G. ;
Gunawardena, Shanaka R. ;
Leggett, Barbara A. ;
Gattas, Michael ;
Boussioutas, Alex ;
Ahnen, Dennis J. ;
Baron, John A. ;
Parry, Susan ;
Goldblatt, Jack ;
Young, Joanne P. ;
Hopper, John L. ;
Jenkins, Mark A. .
HUMAN MUTATION, 2013, 34 (03) :490-497
[10]   5′ flanking variants of resistin are associated with obesity [J].
Engert, JC ;
Vohl, MC ;
Williams, SM ;
Lepage, P ;
Loredo-Osti, JC ;
Faith, J ;
Doré, C ;
Renaud, Y ;
Burtt, NP ;
Villeneuve, A ;
Hirschhorn, JN ;
Altshuler, D ;
Groop, LC ;
Després, JP ;
Gaudet, D ;
Hudson, TJ .
DIABETES, 2002, 51 (05) :1629-1634